Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma. Zheng DX, Jenkins RW. Br J Dermatol 2024 Nov 15:ljae445. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zheng DX, Jenkins RW. Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma. Br J Dermatol 2024 Nov 15:ljae445. doi: 10.1093.
PMID: 39545493